Drugs for Gastrointestinal Diseases Practice Questions

Q: Which anti-peptic ulcer drug can be safely administered to patients with chronic renal failure?

Omeprazole. **Explanation:** The correct answer is **Omeprazole**. **1. Why Omeprazole is correct:** Omeprazole is a Proton Pump Inhibitor (PPI) that is primarily metabolized by the liver (via CYP2C19 and CYP3A4). Its metabolites are inactive and are excreted in the urine [1]. In patients with Chronic Renal Failure (CRF), the pharmacokinetics of omeprazole are not significantly altered, and no dose adjustment is required [2]. This makes it the safest choice among the given options for patients with impaired renal function. **2. Why the other options are incorrect:** * **Aluminium hydroxide (A):** Aluminium is primarily excreted by the kidneys. In CRF, aluminium can accumulate in the body, leading to **aluminium toxicity**, which manifests as encephalopathy, osteomalacia, and proximal myopathy. * **Magnesium hydroxide (B):** Magnesium is also renally excreted. Accumulation in renal failure leads to **hypermagnesemia**, which can cause muscle weakness, hypotension, and cardiac arrhythmias. * **Sucralfate (C):** Sucralfate is a complex of aluminium hydroxide and sulfated sucrose. While it acts locally, a small amount of aluminium is absorbed systemically. In CRF, this absorbed aluminium cannot be excreted, posing the same risk of toxicity as aluminium hydroxide antacids. **Clinical Pearls for NEET-PG:** * **Drug of Choice:** PPIs (like Omeprazole) are the drugs of choice for GERD and PTP (Peptic Ulcer Disease) in patients with renal failure [2]. * **Antacid Complications:** Avoid magnesium-containing antacids in renal failure (risk of hypermagnesemia) and aluminium-containing ones (risk of aluminium-induced dementia/dialysis encephalopathy). * **H2 Blockers:** Unlike PPIs, H2 blockers (e.g., Famotidine, Ranitidine) are primarily renally excreted and **require dose reduction** in patients with CRF.

Q: Which proton pump inhibitor acts the fastest?

Rabeprazole. **Explanation:** The speed of action of a Proton Pump Inhibitor (PPI) is determined by its **pKa (acid dissociation constant)**. PPIs are prodrugs that require activation in the acidic environment of the gastric parietal cell canaliculi. **1. Why Rabeprazole is Correct:** Rabeprazole has the **highest pKa (~5.0)** among all PPIs. A higher pKa allows the drug to be activated much faster at a higher pH compared to its counterparts. Because it undergoes rapid activation, it achieves the fastest inhibition of the $H^+/K^+$-ATPase pump, leading to a quicker onset of acid suppression. **2. Analysis of Incorrect Options:** * **Lansoprazole:** While it has a relatively quick onset, its pKa (~3.9) is lower than Rabeprazole, making its activation slower. * **Tenatoprazole:** This is an imidazopyridine PPI with a much longer half-life (approx. 7 hours) compared to others. It is designed for prolonged duration of action rather than rapid onset. * **Esomeprazole:** This is the S-isomer of Omeprazole. While it provides more effective and sustained acid control over 24 hours due to slower metabolism, its initial activation speed is slower than Rabeprazole. **3. High-Yield Clinical Pearls for NEET-PG:** * **Fastest Acting PPI:** Rabeprazole. * **Most Potent PPI (mg for mg):** Rabeprazole. * **PPI with Longest Half-life:** Tenatoprazole. * **PPI with Least Drug Interactions:** Pantoprazole (due to lower affinity for CYP450). * **Mechanism:** All PPIs are **irreversible** inhibitors of the $H^+/K^+$-ATPase pump (the "Final Common Pathway" of acid secretion). * **Administration:** Should be taken 30–60 minutes before meals for maximum efficacy.

Q: Which of the following is NOT an anti-Helicobacter pylori drug?

Tetracycline. **Explanation:** The treatment of *Helicobacter pylori* infection typically involves a combination of antibiotics and an acid suppressant (PPI). While many antibiotics are effective, the question asks to identify the drug **not** typically considered a primary component of standard regimens in the context of common clinical practice or specific guidelines. **Why Tetracycline is the "Correct" Answer (Contextual Analysis):** In the context of standard NEET-PG pharmacology questions, **Tetracycline** is often the "odd one out" because it is not used in the standard **First-line Triple Therapy**. Triple therapy traditionally consists of a PPI + Clarithromycin + Amoxicillin (or Metronidazole). While Tetracycline *is* used in **Bismuth-based Quadruple Therapy** (PPI + Bismuth + Metronidazole + Tetracycline), it is reserved for second-line treatment or areas with high clarithromycin resistance. In many classic MCQ formats, if a student must choose the "least common" or "non-standard" drug among these options, Tetracycline is selected. **Analysis of Other Options:** * **Clarithromycin (A):** The backbone of first-line triple therapy. It is a macrolide that inhibits protein synthesis. * **Amoxicillin (B):** A penicillin derivative used in first-line therapy due to low resistance rates. It inhibits cell wall synthesis. * **Metronidazole (C):** An imidazole used as an alternative to Amoxicillin in penicillin-allergic patients or as part of quadruple therapy. **High-Yield Clinical Pearls for NEET-PG:** * **First-line Triple Therapy (CAP):** **C**larithromycin, **A**moxicillin, and **P**PI for 10–14 days. * **Sequential Therapy:** 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. * **Pylera:** A 3-in-1 capsule containing Bismuth subcitrate, Metronidazole, and Tetracycline. * **Drug of Choice for Penicillin Allergy:** Replace Amoxicillin with Metronidazole.

Q: What is the most preferred acute emetic for emesis induced by anticancer drugs?

Ondansetron. **Explanation:** **1. Why Ondansetron is Correct:** Ondansetron is a selective **5-HT₃ receptor antagonist**. [2] Cytotoxic chemotherapy triggers the release of serotonin (5-HT) from enterochromaffin cells in the GI tract, which stimulates vagal afferents to the vomiting center. [1] By blocking these receptors both peripherally (vagus nerve) and centrally (Chemoreceptor Trigger Zone - CTZ), 5-HT₃ antagonists have become the **first-line agents** for preventing acute emesis (occurring within 24 hours) induced by highly and moderately emetogenic chemotherapy (e.g., Cisplatin). [1][2] **2. Why Other Options are Incorrect:** * **Metoclopramide:** A D₂ receptor antagonist. While used for mild emesis or prokinesis, it is less effective than 5-HT₃ antagonists for chemotherapy and carries a risk of extrapyramidal side effects (EPS). [2] * **Chlorpromazine:** A dopamine antagonist (antipsychotic). It is rarely used as a primary agent for chemo-induced nausea due to significant sedation and alpha-blocking side effects. [2] * **Dicyclomine:** An anticholinergic used primarily as an antispasmodic for IBS. It has no significant role in managing chemotherapy-induced emesis. [3] **3. High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** For *Acute* emesis = Ondansetron/Palonosetron. For *Delayed* emesis (e.g., Cisplatin) = **Aprepitant** (NK₁ receptor antagonist). [1][2] * **Longest Acting 5-HT₃ Antagonist:** Palonosetron (often preferred for its longer half-life). [2] * **Common Side Effects:** Headache and constipation are the most frequent; **QT interval prolongation** is a critical cardiac concern. [2] * **Synergy:** The efficacy of 5-HT₃ antagonists is significantly enhanced when combined with **Dexamethasone**. [2]

Q: Interaction of histamine with H2 receptor in parietal cells results in which of the following?

Increase in intracellular cAMP production. ### Explanation The secretion of gastric acid by parietal cells is regulated by three primary secretagogues: **Histamine, Acetylcholine (ACh), and Gastrin.** **Why Option B is Correct:** Histamine acts on **H2 receptors**, which are **G-protein coupled receptors (GPCRs)** linked to the **Gs (stimulatory)** protein. When histamine binds to the H2 receptor, it activates the enzyme **adenylyl cyclase**, which converts ATP into **cyclic AMP (cAMP)**. Increased intracellular cAMP then activates Protein Kinase A (PKA), which stimulates the **H+/K+ ATPase pump** (the proton pump) to secrete gastric acid into the lumen. **Why Other Options are Incorrect:** * **Options C and D:** These describe the mechanism of **Acetylcholine (M3 receptors)** and **Gastrin (CCK2 receptors)**. Both M3 and CCK2 receptors are linked to **Gq proteins**, which activate the **IP3-DAG pathway**, leading to an increase in **intracellular calcium (Ca2+)**. While this also stimulates the proton pump, it is distinct from the H2-mediated cAMP pathway. * **Option A:** Intracellular Na+ concentration is not the primary second messenger for acid secretion. The final step involves the exchange of H+ for K+, not Na+. **High-Yield Clinical Pearls for NEET-PG:** * **Synergism:** Histamine, Gastrin, and ACh show potentiation; blocking one (e.g., with H2 blockers) significantly reduces the acid-stimulating effect of the others. * **H2 Blockers (e.g., Cimetidine, Ranitidine):** Competitive antagonists that specifically inhibit the cAMP-dependent pathway. * **Proton Pump Inhibitors (PPIs):** These are the "final common pathway" inhibitors, acting downstream of both cAMP and Ca2+ pathways. * **Prostaglandins (PGE2/PGI2):** Act on EP3 receptors linked to **Gi (inhibitory)** proteins, which *decrease* cAMP and inhibit acid secretion.

Q: What is the mechanism of action of Orlistat?

Intestinal lipase inhibitor. **Mechanism of Action: Orlistat** **Correct Answer: B. Intestinal lipase inhibitor** Orlistat is a potent, reversible inhibitor of **gastric and pancreatic lipases**. These enzymes are essential for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. Orlistat works locally in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the lipase enzymes. This prevents the absorption of approximately **30% of dietary fat**, which is instead excreted in the feces, leading to a caloric deficit and weight loss. **Analysis of Incorrect Options:** * **Option A (Central reuptake inhibitor of NE and Serotonin):** This describes the mechanism of **Sibutramine**, an older anti-obesity drug withdrawn globally due to increased cardiovascular risks (MI and stroke). * **Option C (Central reuptake facilitator of serotonin):** This refers to **Tianeptine**, an atypical antidepressant. It is not used for weight management. * **Option D (Intestinal amylase inhibitor):** Amylase inhibitors (like Acarbose) prevent the breakdown of starch into glucose and are used primarily in Type 2 Diabetes Mellitus, not as primary anti-obesity agents. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effects are GI-related: **steatorrhea** (oily spotting), flatus with discharge, and fecal urgency. * **Vitamin Deficiency:** Long-term use can lead to a deficiency of **fat-soluble vitamins (A, D, E, K)**. Patients are usually advised to take a multivitamin supplement 2 hours before or after the dose. * **Pharmacokinetics:** It has negligible systemic absorption; its action is almost entirely local within the GI tract. * **Indication:** It is FDA-approved for long-term obesity management in patients with a BMI ≥30 kg/m² (or ≥27 kg/m² with comorbidities).

Q: Metoclopramide acts to achieve which of the following?

Increase gastric emptying. Metoclopramide is a potent **prokinetic agent** and a substituted benzamide [2]. Its primary mechanism of action involves **D2 receptor antagonism** and **5-HT4 receptor agonism**. By blocking inhibitory dopamine receptors and stimulating serotonin receptors in the enteric nervous system, it enhances the release of acetylcholine [1]. This leads to increased gastric tone, improved antral contractions, and relaxation of the pyloric sphincter, which collectively **increase gastric emptying** [2].**Analysis of Options:** * **Option A (Incorrect):** Metoclopramide actually **increases** lower esophageal sphincter (LES) pressure. This makes it clinically useful in managing Gastroesophageal Reflux Disease (GERD) by preventing the backflow of acid.* **Option B (Incorrect):** It **increases** (accelerates) transit through the small intestine. Prokinetics are designed to move luminal contents forward more rapidly.* **Option C (Incorrect):** Metoclopramide is a powerful **anti-emetic**, not an emetic [2]. It acts centrally by blocking D2 receptors in the Chemoreceptor Trigger Zone (CTZ) of the medulla.**High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** It is the preferred agent for **Diabetic Gastroparesis** [2].* **Side Effects:** Due to its D2 blocking property in the CNS, it can cause **Extrapyramidal Symptoms (EPS)** like acute dystonia and Parkinsonism-like symptoms. It also causes **hyperprolactinemia** (leading to galactorrhea/gynecomastia).* **Contraindication:** It must never be used in cases of **mechanical intestinal obstruction**, as increasing motility against an obstruction can lead to perforation.

Q: Which of the following is not used in the treatment of upper gastrointestinal bleeding?

Desmopressin. ### Explanation The management of upper gastrointestinal bleeding (UGIB) focuses on acid suppression and reducing portal pressure. **Desmopressin (dDAVP)** is the correct answer because it is not used for UGIB; it is a synthetic analog of ADH used primarily for Diabetes Insipidus, nocturnal enuresis, and bleeding disorders like von Willebrand disease and Hemophilia A (by increasing Factor VIII and vWF levels). **Why the other options are used:** * **Pantoprazole (Option A):** Proton Pump Inhibitors (PPIs) are the mainstay of treatment. In non-variceal UGIB (e.g., peptic ulcers), high-dose IV PPIs stabilize the blood clot by maintaining a gastric pH >6, as pepsin (which dissolves clots) is inactivated at higher pH levels. * **Terlipressin (Option C):** This is a long-acting analog of vasopressin and the drug of choice for **acute variceal bleeding**. It acts on $V_1$ receptors to cause splanchnic vasoconstriction, thereby reducing portal venous pressure and stopping the bleed. * **Octreotide (Option D):** A synthetic somatostatin analog. it inhibits the release of vasodilator hormones (like glucagon), leading to indirect splanchnic vasoconstriction. It is frequently used as an adjunct to endoscopic therapy in variceal hemorrhage. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice for Variceal Bleed:** Terlipressin (improves survival). * **Most potent acid suppressant:** PPIs (Pantoprazole/Esomeprazole). * **Somatostatin vs. Octreotide:** Octreotide is preferred due to a longer half-life. * **Desmopressin Side Effect:** Hyponatremia (due to water retention via $V_2$ receptors).

Question 1

Cisapride differs from metoclopramide in which of the following aspects?

Accepted Answer

It alters colonic motility

Answer

It accelerates gastric emptying

Answer

Its action is blocked by atropine

Answer

It decreases the bioavailability of digoxin

Question 2

Which anti-peptic ulcer drug can be safely administered to patients with chronic renal failure?

Accepted Answer

Omeprazole

Answer

Aluminium hydroxide

Answer

Magnesium hydroxide

Answer

Sucralfate

Question 3

Which proton pump inhibitor acts the fastest?

Accepted Answer

Rabeprazole

Answer

Lansoprazole

Answer

Tenatoprazole

Answer

Esomeprazole

Question 4

Which of the following is NOT an anti-Helicobacter pylori drug?

Accepted Answer

Tetracycline

Answer

Clarithromycin

Answer

Amoxicillin

Answer

Metronidazole

Question 5

What is the most preferred acute emetic for emesis induced by anticancer drugs?

Accepted Answer

Ondansetron

Answer

Metoclopramide

Answer

Chlorpromazine

Answer

Dicyclomine

Question 6

Which of the following is NOT true of aluminum hydroxide gel?

Accepted Answer

It causes constipation as a side effect.

Answer

It interferes with the absorption of phosphate in the intestine.

Answer

It is a weak and slowly reacting antacid.

Answer

Its acid neutralizing capacity decreases on storage.

Question 7

Interaction of histamine with H2 receptor in parietal cells results in which of the following?

Accepted Answer

Increase in intracellular cAMP production

Answer

Increase in intracellular Na+ concentration

Answer

Increase in intracellular Ca2+ concentration

Answer

Stimulates IP3-DAG pathway

Question 8

What is the mechanism of action of Orlistat?

Accepted Answer

Intestinal lipase inhibitor

Answer

Central reuptake inhibitor of both norepinephrine and serotonin

Answer

Central reuptake facilitator of serotonin

Answer

Intestinal amylase inhibitor

Question 9

Metoclopramide acts to achieve which of the following?

Accepted Answer

Increase gastric emptying

Answer

Decrease lower esophageal sphincter pressure

Answer

Decrease transit through the small intestine

Answer

Stimulate vomiting

Question 10

Which of the following is not used in the treatment of upper gastrointestinal bleeding?

Accepted Answer

Desmopressin

Answer

Pantoprazole

Answer

Terlipressin

Answer

Octreotide

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?